`25
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT 35
`
`TO DECLARATION OF CHRISTIANA GARRETT
`IN SUPPORT OF NUVASIVE, INC.’S
`REPLY IN SUPPORT OF
`MOTION FOR PARTIAL SUMMARY JUDGMENT
`AND MOTION TO EXCLUDE EXPERT OPINIONS
`(IMPLANT PATENTS)
`
`
`
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30335 Page 2 of
`25
`
`· · · · · · UNITED STATES DISTRICT COURT
`
`· · · · · ·SOUTHERN DISTRICT OF CALIFORNIA
`
`· · · · · · · · ·SAN DIEGO DIVISION
`
`NUVASIVE, INC., a Delaware
`corporation,
`
`· · · · · Plaintiff,
`
`· · · · · v.· · · · ·Case No. 3:18-CV-00347
`· · · · · · · · · · · · · · · -CAB-MDD
`ALPHATEC HOLDINGS, INC., a
`Delaware corporation and
`ALPHATEC SPINE, INC., a
`California corporation,
`
`· · · · · Defendants.
`
`_______________________________________________________
`
`· · ·HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY
`
`· · · · VIDEOTAPED DEPOSITION OF FRANK CHANG
`
`· ·ALPHATEC’S HOLDINGS, INC. RULE 30(b)(6) WITNESS
`
`· · · · · · · · SAN DIEGO, CALIFORNIA
`
`· · · · · · · · · JANUARY 15, 2020
`
`REPORTED BY:· PATRICIA Y. SCHULER, CSR No. 11949
`
`EXHIBIT 35
`Page 126
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30336 Page 3 of
`25
`
`·1· · · · · · · ·UNITED STATES DISTRICT COURT
`
`·2· · · · · · · SOUTHERN DISTRICT OF CALIFORNIA
`
`·3· · · · · · · · · · SAN DIEGO DIVISION
`
`·4
`
`·5· ·NUVASIVE, INC., a Delaware
`· · ·corporation,
`·6
`· · · · · · · ·Plaintiff,
`·7
`· · · · · · · ·v.· · · · · · ·Case No. 3:18-CV-00347
`·8· · · · · · · · · · · · · · · · · · ·-CAB-MDD
`· · ·ALPHATEC HOLDINGS, INC., a
`·9· ·Delaware corporation and
`· · ·ALPHATEC SPINE, INC., a
`10· ·California corporation,
`
`11· · · · · · ·Defendants.
`
`12· ·_______________________________________________________
`
`13· · · · Videotaped deposition of FRANK CHANG, taken on
`
`14· ·behalf of the Defendants at 12235 El Camino Real,
`
`15· ·Suite 100, San Diego, California, at 9:03 a.m. and
`
`16· ·ending at 6:17 p.m., on January 15, 2020, before
`
`17· ·PATRICIA Y. SCHULER, Certified Shorthand Reporter
`
`18· ·No. 11949.
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`EXHIBIT 35
`Page 127
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30337 Page 4 of
`25
`
`·1· ·APPEARANCES:
`
`·2· ·FOR PLAINTIFF:
`
`·3· · · · · · ·WILSON SONSINI GOODRICH & ROSATI, P.C.
`
`·4· · · · · · ·BY:· PAUL D. TRIPODI, II, ESQ.
`
`·5· · · · · · ·633 West Fifth Street
`
`·6· · · · · · ·Suite 1550
`
`·7· · · · · · ·Los Angeles, California· 90071
`
`·8· · · · · · ·Ptripodi@wsgr.com
`
`·9· · · · · · ·- and -
`
`10· · · · · · ·WILSON SONSINI GOODRICH & ROSATI, P.C.
`
`11· · · · · · ·BY:· CHRISTINA DASHE, ESQ.
`
`12· · · · · · ·12235 El Camino Real
`
`13· · · · · · ·Suite 200
`
`14· · · · · · ·San Diego, California· 92130
`
`15· · · · · · ·CDashe@wsgr.com
`
`16· ·FOR DEFENDANTS:
`
`17· · · · · · ·WINSTON STRAWN LLP
`
`18· · · · · · ·BY:· BRIAN J. NISBET, ESQ.
`
`19· · · · · · ·35 West Wacker Drive
`
`20· · · · · · ·Chicago, Illinois 60601-9703
`
`21· · · · · · ·bnisbet@winston.com
`
`22· ·VIDEOGRAPHER:· TY PAULSON
`
`23· ·ALSO PRESENT:· TYSON MARSHALL
`
`24· · · · · · · · · KATE CORLEW
`
`25
`
`EXHIBIT 35
`Page 128
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30338 Page 5 of
`25
`
`·1· · · · · · · · · · · · ·I-N-D-E-X
`
`·2· ·WITNESS:· · · · · · · · · · · · · · · · ·EXAMINATION
`
`·3· ·FRANK CHANG· · · · · · · · · · · · · · · · · · ·PAGE
`
`·4· ·MS. DASHE· · · · · · · · · · · · · · · · · · · · · 9
`
`·5
`
`·6· · · · · · · · · · · E-X-H-I-B-I-T-S
`
`·7· ·PLAINTIFF'S· · · · · · · · · · · · · · · · · · ·PAGE
`
`·8· ·Exhibit 1· · ·Document entitled "NuVasive· · · · ·13
`· · · · · · · · · ·Inc.'s Amended Second Notice of
`·9· · · · · · · · ·Deposition of Alphatec Holdings
`· · · · · · · · · ·Inc. and Alphatec Spine Inc.
`10· · · · · · · · ·pursuant to rule 30(b)6"
`
`11· ·Exhibit 2· · ·Document entitled "NuVasive· · · · ·14
`· · · · · · · · · ·Inc.'s Second Notice of
`12· · · · · · · · ·Deposition of Alphatec Holdings
`· · · · · · · · · ·Inc. and Alphatec Spine Inc.
`13· · · · · · · · ·pursuant to rule 30(b)6"
`
`14· ·Exhibit 3· · ·Document entitled "2016· · · · · · ·79
`· · · · · · · · · ·Performance Management Form"
`15
`· · ·Exhibit 4· · ·Document entitled "LLIF Retractor· ·90
`16· · · · · · · · ·Test Protocol" dated January 7,
`· · · · · · · · · ·2015
`17
`· · ·Exhibit 5· · ·Document Bates stamped· · · · · · · 92
`18· · · · · · · · ·ATEC_LLIF000151174
`
`19· ·Exhibit 6· · ·Document Bates stamped ATEC_LLIF· · 95
`· · · · · · · · · ·863096
`20
`· · ·Exhibit 7· · ·Document entitled "Battalion· · · ·148
`21· · · · · · · · ·Lateral Lumbar Spacer System,"
`· · · · · · · · · ·Bates stamped NUVA_ATEC00144447
`22· · · · · · · · ·through 14475
`
`23· ·Exhibit 8· · ·Document entitled "Case Notes,"· · 175
`· · · · · · · · · ·Bates stamped ATEC_LLIF000854960
`24· · · · · · · · ·through 963
`
`25
`
`EXHIBIT 35
`Page 129
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30339 Page 6 of
`25
`
`·1· · · · · · · · E-X-H-I-B-I-T-S (CONTINUED)
`
`·2· ·PLAINTIFF'S· · · · · · · · · · · · · · · · · · ·PAGE
`
`·3· ·Exhibit 9· · ·Document entitled "Case Notes,"· · 191
`· · · · · · · · · ·Bates stamped ATEC_LLIF000854978
`·4· · · · · · · · ·through 983
`
`·5· ·Exhibit 10· · Document entitled "Case Notes,"· · 207
`· · · · · · · · · ·Bates stamped ATEC_LLIF00854994
`·6· · · · · · · · ·through 999
`
`·7· ·Exhibit 11· · Document entitled "Case Notes,"· · 223
`· · · · · · · · · ·Bates stamped ATEC_LLIF000855000
`·8· · · · · · · · ·through 004
`
`·9· ·Exhibit 12· · Document entitled "Case Notes,"· · 234
`· · · · · · · · · ·Bates stamped ATEC_LLIF000855000
`10· · · · · · · · ·through 11
`
`11· ·Exhibit 13· · Document entitled "Case Notes,"· · 242
`· · · · · · · · · ·Bates stamped ATEC_LLIF000672779
`12· · · · · · · · ·through 782
`
`13· ·Exhibit 14· · Document entitled "Squadron with· ·254
`· · · · · · · · · ·Arsenal case review, Paul Sawin
`14· · · · · · · · ·M.D.," Bates stamped
`· · · · · · · · · ·ATEC_LLIF00618461 through 480
`15
`· · ·Exhibit 15· · Document entitled "Visiting· · · · 261
`16· · · · · · · · ·Surgeon Program," Bates stamped
`· · · · · · · · · ·ATEC_LLIF00004729
`17
`· · ·Exhibit 16· · Document entitled "R&D Meeting,· · 268
`18· · · · · · · · ·Bates stamped ATEC_LLIF000627235
`
`19· ·Exhibit 17· · Defendant's Second Amended· · · · ·276
`· · · · · · · · · ·Response to Plaintiff NuVasive,
`20· · · · · · · · ·Inc.'s First Set of
`· · · · · · · · · ·Interrogatories, No. 2"
`21
`· · ·Exhibit 18· · Verification· · · · · · · · · · · ·276
`22
`· · ·Exhibit 19· · Document entitled "Defendant's· · ·282
`23· · · · · · · · ·Responses to Plaintiff NuVasive,
`· · · · · · · · · ·Inc.'s Third Set of
`24· · · · · · · · ·Interrogatories, No. 17"
`
`25
`
`EXHIBIT 35
`Page 130
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30340 Page 7 of
`25
`
`·1· · · · · · · · E-X-H-I-B-I-T-S (CONTINUED)
`
`·2· ·PLAINTIFF'S· · · · · · · · · · · · · · · · · · ·PAGE
`
`·3· ·Exhibit 20· · Redacted and excerpted portion of· 296
`· · · · · · · · · ·the rebuttal expert report of
`·4· · · · · · · · ·Keith Ugone, Ph.D., dated
`· · · · · · · · · ·December 4, 2019
`·5
`· · ·Exhibit 21· · Emails Bates stamped· · · · · · · ·322
`·6· · · · · · · · ·ATEC_LLIF000856178 through 180
`
`·7· ·Exhibit 22· · Document entitled "Attachment 4,· ·330
`· · · · · · · · · ·surgeon survey," Bates stamped
`·8· · · · · · · · ·ATEC_LLIF 200864 through 889
`
`·9· ·Exhibit 23· · Document entitled "Lateral· · · · ·340
`· · · · · · · · · ·Training," Bates stamped
`10· · · · · · · · ·ATEC_LLIF000878140 through 171
`
`11· ·Exhibit 24· · Document entitled "Market Launch· ·344
`· · · · · · · · · ·Plan," Bates stamped
`12· · · · · · · · ·ATEC_LLIF000862396 through 403
`
`13· ·Exhibit 25· · Document Bates stamped· · · · · · ·345
`· · · · · · · · · ·ATEC_LLIF000924924
`14
`· · ·Exhibit 26· · Document entitled "A Powerful· · · 348
`15· · · · · · · · ·Value Creation Opportunity,"
`· · · · · · · · · ·Bates stamped ATEC_LLIF000942942
`16· · · · · · · · ·through 958
`
`17· ·Exhibit 27· · Document Bates stamped· · · · · · ·350
`· · · · · · · · · ·ATEC_LLIF000921912 through 943
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`EXHIBIT 35
`Page 131
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30341 Page 8 of
`25
`
`·1· ·SAN DIEGO, CALIFORNIA; WEDNESDAY, JANUARY 15, 2020
`
`·2· · · · · · · · · · · · ·9:03 a.m.
`
`·3· · · · · · ·THE VIDEOGRAPHER:· Good morning.· We are
`
`·4· ·on the record at 9:03 a.m., on January 15, 2020.
`
`·5· ·Audio and video recording will continue to take
`
`·6· ·place until all parties agree to go off the record.
`
`·7· ·Please note that the microphones are sensitive and
`
`·8· ·may pick up whispering and private conversations.
`
`·9· · · · · · ·This is a video-recorded deposition of
`
`10· ·Frank Chang, in the matter of NuVasive v. Alphatec
`
`11· ·Holdings, taken by counsel for the plaintiffs,
`
`12· ·filed in the United States District Court, Southern
`
`13· ·District of California, San Diego Division.
`
`14· · · · · · ·This deposition is taking place at
`
`15· ·Wilson, Sonsini, Goodrich & Rosati, located at
`
`16· ·12235 El Camino Real, in San Diego, California
`
`17· ·92130.
`
`18· · · · · · ·My name is Ty Paulson.· I am the
`
`19· ·videographer on behalf of U.S. Legal Support,
`
`20· ·located at 1230 Columbia Street, Suite 400, in
`
`21· ·San Diego, California 92101.
`
`22· · · · · · ·The court reporter is Patricia Schuler,
`
`23· ·on behalf of U.S. Legal Support.· I am not related
`
`24· ·to any party in this action, nor am I financially
`
`25· ·interested in the outcome.
`
`EXHIBIT 35
`Page 132
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30342 Page 9 of
`25
`
`·1· · · · · · ·Counsel will state their appearances for
`
`·2· ·the record, after which the court reporter will
`
`·3· ·swear in the witness.
`
`·4· · · · · · ·MS. DASHE:· Christina Dashe from Wilson
`
`·5· ·Sonsini Goodrich & Rosati, on behalf of plaintiff
`
`·6· ·NuVasive.· With me is my colleague Paul Tripodi,
`
`·7· ·also of Wilson Sonsini, as well as Kate Corlew of
`
`·8· ·NuVasive.
`
`·9· · · · · · ·MR. NISBET:· Brian Nisbet with Winston &
`
`10· ·Strawn, on behalf of the Alphatec entities and the
`
`11· ·witness.· With me is Tyson Marshall, counsel with
`
`12· ·Alphatec.
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`EXHIBIT 35
`Page 133
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30343 Page 10 of
`25
`
`·1· · · · · · · · · · · ·FRANK CHANG,
`
`·2· · called as a witness, having been duly sworn by the
`
`·3· · · court reporter, was examined and testified as
`
`·4· · · · · · · · · · · · ·follows:
`
`·5
`
`·6· · · · · · · · · · · · EXAMINATION
`
`·7· ·BY MS. DASHE:
`
`·8· · · · Q.· ·Good morning.
`
`·9· · · · A.· ·Hi.
`
`10· · · · Q.· ·Please state and spell your full name for
`
`11· ·the record.
`
`12· · · · A.· ·Frank Chang, F-R-A-N-K, C-H-A-N-G.
`
`13· · · · Q.· ·Where do you currently live?
`
`14· · · · A.· ·Carlsbad.
`
`15· · · · Q.· ·California?
`
`16· · · · A.· ·California.
`
`17· · · · Q.· ·Who is your current employer?
`
`18· · · · A.· ·Alphatec Spine.
`
`19· · · · Q.· ·How long have you been employed at
`
`20· ·Alphatec?
`
`21· · · · A.· ·A little over four years.
`
`22· · · · Q.· ·What is your current title?
`
`23· · · · A.· ·Senior design engineer.
`
`24· · · · Q.· ·Have you ever been deposed before?
`
`25· · · · A.· ·No.
`
`EXHIBIT 35
`Page 134
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30344 Page 11 of
`25
`
`·1· ·accused products?
`
`·2· · · · · · ·Do you see that?
`
`·3· · · · A.· ·Okay.· I do see that.
`
`·4· · · · Q.· ·Do you understand, then, that NuVasive
`
`·5· ·generally asked Alphatec to identify any
`
`·6· ·alternative designs or alternative methods that
`
`·7· ·Alphatec contends to be acceptable alternatives to
`
`·8· ·the Battalion lateral system?
`
`·9· · · · A.· ·Recently?
`
`10· · · · · · ·MR. NISBET:· Object to the form of the
`
`11· ·question.
`
`12· ·BY MS. DASHE:
`
`13· · · · Q.· ·It's a document dated October 2019.
`
`14· · · · A.· ·No.
`
`15· · · · Q.· ·What do you understand that sentence to
`
`16· ·be asking?
`
`17· · · · · · ·MR. NISBET:· Object to the form of the
`
`18· ·question.· It is outside the scope.· He doesn't
`
`19· ·have any personal knowledge of it, so I'm not sure
`
`20· ·what the point of that inquiry is.
`
`21· · · · · · ·But you can answer, to the extent you
`
`22· ·understand it.
`
`23· · · · · · ·THE WITNESS:· I'm not really sure. I
`
`24· ·guess whatever the accused product is.· You're
`
`25· ·asking if we have any prospective alternative
`
`EXHIBIT 35
`Page 135
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30345 Page 12 of
`25
`
`·1· ·design or alternative method that we contend to be
`
`·2· ·acceptable and noninfringing to that.
`
`·3· ·BY MS. DASHE:
`
`·4· · · · Q.· ·If you go to Page 5, the first bullet.
`
`·5· ·Do you see where it says "Medtronic retractor
`
`·6· ·systems and surgical techniques, including without
`
`·7· ·limitation Direct Lateral Interbody Fusion (DLIF)
`
`·8· ·and MAST QUADRANT"?
`
`·9· · · · A.· ·Okay.
`
`10· · · · Q.· ·Are you familiar with Medtronic's DLIF or
`
`11· ·MAST QUADRANT?
`
`12· · · · · · ·MR. NISBET:· Object to the form.
`
`13· · · · · · ·THE WITNESS:· I have heard of DLIF, but I
`
`14· ·don't know what it looks like.
`
`15· ·BY MS. DASHE:
`
`16· · · · Q.· ·What have you heard about DLIF?
`
`17· · · · A.· ·That it is direct lateral interbody
`
`18· ·fusion.
`
`19· · · · Q.· ·Is that a lateral access system?
`
`20· · · · A.· ·I have heard of DLIF.· That's about as
`
`21· ·much as I know.· I don't know what is included in
`
`22· ·DLIF.· I have never seen what the tools they
`
`23· ·provide are.
`
`24· · · · Q.· ·Have you ever seen a DLIF surgical guide?
`
`25· · · · A.· ·No.
`
`EXHIBIT 35
`Page 136
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30346 Page 13 of
`25
`
`·1· · · · Q.· ·Do you have any idea what the DLIF --
`
`·2· ·Medtronic DLIF system looks like at all?
`
`·3· · · · A.· ·No.
`
`·4· · · · Q.· ·Have you heard of an entity called
`
`·5· ·Warsaw?
`
`·6· · · · A.· ·Come again?
`
`·7· · · · Q.· ·Warsaw, W-a-r-s-a-w.
`
`·8· · · · A.· ·Like the place in Indiana?
`
`·9· · · · Q.· ·Yes.· Actually, yes.
`
`10· · · · A.· ·Like have I heard -- I have heard of
`
`11· ·Warsaw, Indiana.· I don't know if that is a company
`
`12· ·or an item.· Sorry.
`
`13· · · · Q.· ·You can set that aside.
`
`14· · · · · · ·If you go back to Exhibit 1, please.
`
`15· · · · · · ·MR. NISBET:· Can we take a quick break?
`
`16· · · · · · ·MS. DASHE:· Yeah.· Actually, I think I'm
`
`17· ·transitioning, so we'll take a break.
`
`18· · · · · · ·MR. NISBET:· Okay.
`
`19· · · · · · ·THE WITNESS:· Okay.
`
`20· · · · · · ·THE VIDEOGRAPHER:· We're off the record
`
`21· ·at 4:28 p.m.
`
`22· · · · · · ·(Recess taken.)
`
`23· · · · · · ·THE VIDEOGRAPHER:· We're back on the
`
`24· ·record at 4:39 p.m.
`
`25· ·///
`
`EXHIBIT 35
`Page 137
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30347 Page 14 of
`25
`
`·1· ·BY MS. DASHE:
`
`·2· · · · Q.· ·Welcome back, Mr. Chang.· Before we
`
`·3· ·broke, I had you pull out Exhibit 1.
`
`·4· · · · · · ·Do you have that in front of you?
`
`·5· · · · A.· ·I do.
`
`·6· · · · Q.· ·If you go to Page 10, again, please, and
`
`·7· ·go to Topic No. 6.· Let me know when you're there.
`
`·8· · · · A.· ·6?
`
`·9· · · · Q.· ·Yes.
`
`10· · · · A.· ·Yes.
`
`11· · · · Q.· ·Do you understand that you have been
`
`12· ·designated to provide testimony regarding
`
`13· ·Alphatec's corporate knowledge regarding Topic
`
`14· ·No. 6?
`
`15· · · · A.· ·Yes.
`
`16· · · · · · ·MR. NISBET:· And, again, subject to
`
`17· ·conversations and objections.
`
`18· ·BY MS. DASHE:
`
`19· · · · Q.· ·Do you see that Topic 6 is "Alphatec's
`
`20· ·ability to develop bring to market a two-bladed
`
`21· ·retractor according to the Warsaw patents -- and it
`
`22· ·lists three patents -- including Alphatec's
`
`23· ·development time and cost of developing and
`
`24· ·manufacturing a two-bladed retractor and market
`
`25· ·acceptance of a two-bladed retractor."
`
`EXHIBIT 35
`Page 138
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30348 Page 15 of
`25
`
`·1· · · · · · ·Do you see that?
`
`·2· · · · A.· ·I see that.
`
`·3· · · · Q.· ·Does the usage of the term "Warsaw
`
`·4· ·patent" in Topic 6 help refresh your recollection
`
`·5· ·as to who Warsaw may be?
`
`·6· · · · A.· ·No.
`
`·7· · · · Q.· ·Do you see the three patents listed under
`
`·8· ·Topic 6?
`
`·9· · · · A.· ·I do.
`
`10· · · · Q.· ·Did you look at those three patents in
`
`11· ·preparing for your deposition testimony today?
`
`12· · · · A.· ·I have not.
`
`13· · · · Q.· ·Do you have any patents?
`
`14· · · · A.· ·No.
`
`15· · · · Q.· ·What did you do to prepare to provide
`
`16· ·Alphatec's knowledge with respect to Topic 6?
`
`17· · · · A.· ·I spoke to our counsel and Scott.
`
`18· · · · Q.· ·What did you speak with Scott Robinson
`
`19· ·about?
`
`20· · · · A.· ·General information on what it takes.
`
`21· · · · Q.· ·What do you mean by "what it takes"?
`
`22· · · · A.· ·What resources are necessary.· Again, I'm
`
`23· ·a design engineer, not a budgeting expert or a --
`
`24· ·what do you want to call it?· Just an executive in
`
`25· ·R & D who has seen the entire process from above.
`
`EXHIBIT 35
`Page 139
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30349 Page 16 of
`25
`
`·1· · · · Q.· ·And what -- what are the -- strike that.
`
`·2· · · · · · ·What resources -- strike that.
`
`·3· · · · · · ·What is your understanding of the
`
`·4· ·two-bladed retractor referred to in Topic 6?
`
`·5· · · · · · ·MR. NISBET:· Objection to the form;
`
`·6· ·vague.
`
`·7· · · · · · ·THE WITNESS:· In Topic 6?
`
`·8· ·BY MS. DASHE:
`
`·9· · · · Q.· ·Yes.
`
`10· · · · A.· ·It would be a retractor with two blades.
`
`11· · · · Q.· ·What did Scott Robinson tell you about
`
`12· ·the resource required to develop a two-bladed
`
`13· ·retractor?
`
`14· · · · A.· ·In relation to what aspect?· Materials?
`
`15· · · · Q.· ·Generally, what did he tell you during
`
`16· ·your conversations in preparing for today's
`
`17· ·deposition?
`
`18· · · · A.· ·That we had the ability at that time to
`
`19· ·do so, or -- and still do.
`
`20· · · · Q.· ·Is this a two-bladed retractor for
`
`21· ·lateral surgery?
`
`22· · · · A.· ·Yes.
`
`23· · · · Q.· ·What else did Scott Robinson tell you in
`
`24· ·your conversations regarding this topic?
`
`25· · · · A.· ·To perform -- or to -- sorry.· To bring
`
`EXHIBIT 35
`Page 140
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30350 Page 17 of
`25
`
`·1· ·to market a two-bladed retractor, we would require,
`
`·2· ·obviously, certain resources.· Those being
`
`·3· ·engineering resources, possibly a surgeon team,
`
`·4· ·prototyping -- so machine, time, and materials.
`
`·5· · · · Q.· ·What is machine time and materials?
`
`·6· · · · A.· ·To get something like an access
`
`·7· ·instrument done, or really any instrument cut out
`
`·8· ·of metal -- all instruments are pretty much cut out
`
`·9· ·of metal unless they're PEK or plastic -- but even
`
`10· ·then, you need machine time.· You know, need to
`
`11· ·basically reserve time on a machine from a
`
`12· ·manufacturer, or within our own capacities within
`
`13· ·our company in the machine shop we call "tag."· So
`
`14· ·reserving time in tag to have prototypes made which
`
`15· ·speeds up the process mightily.
`
`16· · · · Q.· ·Aside from speaking with Scott Robinson
`
`17· ·and counsel, did you do anything else to prepare to
`
`18· ·provide Alphatec's knowledge with respect to Topic
`
`19· ·6?
`
`20· · · · A.· ·No.
`
`21· · · · Q.· ·Did you look at any documents?
`
`22· · · · A.· ·No.
`
`23· · · · Q.· ·Alphatec did not actually develop a
`
`24· ·two-bladed lateral retractor, did it?
`
`25· · · · A.· ·At that time?
`
`EXHIBIT 35
`Page 141
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30351 Page 18 of
`25
`
`·1· · · · Q.· ·At any time.
`
`·2· · · · A.· ·We have nothing on the market.
`
`·3· · · · Q.· ·You do not have a commercially available
`
`·4· ·two-bladed retractor for lateral fusion surgery; is
`
`·5· ·that correct?
`
`·6· · · · A.· ·That is correct.
`
`·7· · · · Q.· ·Have you ever had a two-bladed -- has
`
`·8· ·Alphatec ever had a two-bladed retractor for
`
`·9· ·lateral fusion spine surgery?
`
`10· · · · A.· ·How is that different from the last
`
`11· ·question?· No, we -- we do not have a commercially
`
`12· ·available retractor, and nor have we had one in the
`
`13· ·past.· Sorry.
`
`14· · · · Q.· ·So this two-bladed retractor that you
`
`15· ·spoke with Mr. Robinson about, that would be a
`
`16· ·hypothetical retractor; is that right?
`
`17· · · · A.· ·We are currently in development of one as
`
`18· ·well.
`
`19· · · · Q.· ·When you spoke with Mr. Robinson, did you
`
`20· ·rely on any of -- excuse me.
`
`21· · · · · · ·When you spoke with Mr. Robinson, did he
`
`22· ·rely on any of Alphatec's experiences with the
`
`23· ·current development of a two-bladed retractor?
`
`24· · · · A.· ·No.· We were talking -- we were talking
`
`25· ·hypotheticals on that time while we were developing
`
`EXHIBIT 35
`Page 142
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30352 Page 19 of
`25
`
`·1· ·the three, if we went to a two, was it possible,
`
`·2· ·and from what I understand, yes, it was possible.
`
`·3· · · · Q.· ·So in preparing for giving testimony on
`
`·4· ·behalf of Alphatec with respect to Topic 6, you
`
`·5· ·were discussing a hypothetical two-bladed
`
`·6· ·retractor; is that right?
`
`·7· · · · A.· ·Yes.
`
`·8· · · · Q.· ·You also said that you're currently in
`
`·9· ·development of a two-bladed retractor?
`
`10· · · · A.· ·That is part of our agenda in 2020.
`
`11· · · · Q.· ·That is --
`
`12· · · · A.· ·Well, 2019-2020.
`
`13· · · · Q.· ·When I say, "you," I mean Alphatec has it
`
`14· ·on its agenda --
`
`15· · · · A.· ·Yes.
`
`16· · · · Q.· ·-- to develop?
`
`17· · · · A.· ·Yes.
`
`18· · · · Q.· ·Is that a lateral retractor?
`
`19· · · · A.· ·I'm actually not privy to what it's
`
`20· ·actually going to be used for.· Potentially, but...
`
`21· · · · Q.· ·So you don't know if the two-bladed
`
`22· ·retractor for development on Alphatec's agenda will
`
`23· ·be used for lateral or something else; is that
`
`24· ·right?
`
`25· · · · A.· ·I think it might be.
`
`EXHIBIT 35
`Page 143
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30353 Page 20 of
`25
`
`·1· · · · Q.· ·Might be used for lateral?
`
`·2· · · · A.· ·It might be, yes.
`
`·3· · · · Q.· ·And how do you know that?
`
`·4· · · · A.· ·Just based on what Scott mentioned.
`
`·5· · · · Q.· ·What did Scott mention?
`
`·6· · · · A.· ·That it -- I think he might have said
`
`·7· ·that it would be used for lateral, but I'm not
`
`·8· ·sure.
`
`·9· · · · Q.· ·And that's Scott Robinson?
`
`10· · · · A.· ·That is Scott Robinson.
`
`11· · · · Q.· ·Is Scott Robinson involved in developing
`
`12· ·the two-bladed retractor that Alphatec has on its
`
`13· ·agenda for 2020?
`
`14· · · · A.· ·No.
`
`15· · · · Q.· ·Do you know who is?
`
`16· · · · A.· ·The access team.
`
`17· · · · Q.· ·What is the access team?
`
`18· · · · A.· ·It's a branch of our product development
`
`19· ·team.
`
`20· · · · Q.· ·Is the two-bladed retractor that Alphatec
`
`21· ·has on its agenda to development in 2020, is that
`
`22· ·meant to be used in conjunction with the Squadron
`
`23· ·retractor?
`
`24· · · · A.· ·No.
`
`25· · · · Q.· ·Is it intended to replace the Squadron
`
`EXHIBIT 35
`Page 144
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30354 Page 21 of
`25
`
`·1· ·retractor?
`
`·2· · · · A.· ·No.
`
`·3· · · · Q.· ·But it might be used for lateral; is that
`
`·4· ·correct?
`
`·5· · · · A.· ·I think so.
`
`·6· · · · Q.· ·And you're not part of the team
`
`·7· ·developing the two-bladed retractor, right?
`
`·8· · · · A.· ·No, I'm on interbody.
`
`·9· · · · Q.· ·If Alphatec had brought the hypothetical
`
`10· ·two-bladed retractor that you're discussing with
`
`11· ·respect to Topic 6, would Alphatec have had to get
`
`12· ·any sort of FDA clearance?
`
`13· · · · A.· ·No.
`
`14· · · · Q.· ·The actual two-bladed retractor that's
`
`15· ·being developed at Alphatec, similarly, that would
`
`16· ·not require any sort of FDA clearance, right?
`
`17· · · · A.· ·The current one?
`
`18· · · · Q.· ·Yes.
`
`19· · · · A.· ·Yes.
`
`20· · · · Q.· ·Do you know what the timeline is for
`
`21· ·developing the Alphatec two-bladed retractor?
`
`22· · · · · · ·MR. NISBET:· Are you talking about the --
`
`23· ·BY MS. DASHE:
`
`24· · · · Q.· ·The currently in development one?
`
`25· · · · A.· ·Oh, the timeline?
`
`EXHIBIT 35
`Page 145
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30355 Page 22 of
`25
`
`·1· · · · Q.· ·Um-hmm.
`
`·2· · · · A.· ·I think we started it in June of 2019,
`
`·3· ·and we're slated to finish within the year, if --
`
`·4· ·around that time.
`
`·5· · · · Q.· ·So that would be about a year and a half?
`
`·6· · · · A.· ·No, no, no.· Within a year.· So, yeah.
`
`·7· · · · Q.· ·Did Mr. Robinson -- strike that.
`
`·8· · · · · · ·So just to make sure that I'm clear, the
`
`·9· ·actual two-bladed retractor that's in development
`
`10· ·started in about June of 2019, and is currently
`
`11· ·slated to be completed on or around June of 2020;
`
`12· ·is that right?
`
`13· · · · A.· ·Yes.· Somewhere around there.
`
`14· · · · Q.· ·Do you know what the status is of the
`
`15· ·actual two-bladed retractor in development at
`
`16· ·Alphatec?
`
`17· · · · · · ·MR. NISBET:· Objection to form.
`
`18· · · · · · ·THE WITNESS:· The status of the current
`
`19· ·one?
`
`20· ·BY MS. DASHE:
`
`21· · · · Q.· ·Yes.
`
`22· · · · A.· ·In development.· I'm sorry, yeah, I'm not
`
`23· ·on the team.
`
`24· · · · Q.· ·Do you know if there's any prototypes?
`
`25· · · · A.· ·I can't speak to that.
`
`EXHIBIT 35
`Page 146
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30356 Page 23 of
`25
`
`·1· · · · · · ·I, PATRICIA Y. SCHULER, a Certified
`
`·2· ·Shorthand Reporter of the State of California, do
`
`·3· ·hereby certify:
`
`·4· · · · · · ·That the foregoing proceedings were taken
`
`·5· ·before me at the time and place herein set forth;
`
`·6· ·that any witnesses in the foregoing proceedings,
`
`·7· ·prior to testifying, were duly sworn; that a
`
`·8· ·verbatim record of the proceedings was made by me
`
`·9· ·using machine shorthand which was thereafter
`
`10· ·transcribed under my direction; that the foregoing
`
`11· ·transcript is a true record of the testimony given.
`
`12· · · · · · ·Further, that if the foregoing pertains
`
`13· ·to the original transcript of a deposition in a
`
`14· ·Federal Case, before completion of the proceedings,
`
`15· ·review of the transcript [X] was [ ] was not
`
`16· ·requested.
`
`17· · · · · · ·I further certify I am neither
`
`18· ·financially interested in the action nor a relative
`
`19· ·or employee of any attorney of party to this
`
`20· ·action.
`
`21· · · · · · ·IN WITNESS WHEREOF, I have this date
`
`22· ·subscribed my name.
`
`23· ·Dated:· January 16, 2020
`
`24· · · · · · · · · · · · · _________________________
`· · · · · · · · · · · · · · PATRICIA Y. SCHULER
`25· · · · · · · · · · · · · CSR NO. 11949
`
`EXHIBIT 35
`Page 147
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30357 Page 24 of
`25
`Deposition Errata Sheet
`Frank Chang
`Deposition Date: January 15,2020
`
`PAGE:LINE
`
`Original Testimony
`
`Corrected
`Testimony
`
`34:17
`
`40:3
`
`48:23
`
`79:17
`
`82:14
`
`83:14
`
`83:15
`
`99:10
`
`109:15
`
`120:20
`
`121:23
`
`136:12
`
`136:23
`
`142:7
`
`163:18
`
`182:6
`
`205:24
`
`206:9
`
`265:20
`
`272:4
`
`"technique"
`
`"discetomy"
`
`"A-C-F"
`
`"disrep"
`
`"pexalobe"
`
`"PEK"
`
`"PEK"
`
`"PEK"
`
`"system"
`
`"what"
`
`"SGG"
`
`"ACDF"
`
`"disc prep"
`
`"hexalobe"
`
`"PEEK"
`
`"PEEK"
`
`"PEEK"
`
`"assessment"
`
`"that"
`
`"STG"
`
`"primary K-wire"
`
`"primary, K-wire"
`
`"pull"
`
`"pull"
`
`"acuate"
`
`"I will be"
`
`"cattawa"
`
`"PEK"
`
`"PEK"
`
`"pawl"
`
`"pawl"
`
`"actuate"
`
`"we are very"
`
`"Cadwell"
`
`"PEEK"
`
`"PEEK"
`
`"Alicia Ruby"
`
`"Ali Shorooghi"
`
`"end"
`
`"AMP"
`
`REASON
`
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`
`EXHIBIT 35
`Page 148
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 311-11 Filed 02/26/21 PageID.30358 Page 25 of
`25
`Deposition Errata Sheet
`Frank Chang
`Deposition Date: January 15, 2020
`
`PAGE:LINE
`
`Original Testimony
`
`Corrected
`Testimony
`
`"TLIF"
`
`'TLIF"
`
`"PEEK"
`
`"PEEK"
`
`"QLIF"
`
`"PLIF"
`
`"PEK"
`
`"PEK"
`
`£>
`
`t&l o
`
`279:13
`
`279:14
`
`290:9
`
`324:10
`
`Date:
`
`Signature:
`
`Frank Chi
`
`REASON
`
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`To correct
`transcription errors
`
`AmericasActive: 14394708.1
`
`EXHIBIT 35
`Page 149
`
`